Skip to main content
. 2017 Aug 31;117(9):1286–1294. doi: 10.1038/bjc.2017.294

Figure 1.

Figure 1

Relationship between RAS mutation status and progression-free and overall survival. (A) progression-free survival and (B) overall survival in patients who were RAS mutated in either pre-treatment biopsy or resected specimen (‘anytime mutant’) versus patients whose specimens only ever tested RAS wild-type.